Patents by Inventor Sau-Chi Betty Yan

Sau-Chi Betty Yan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY FOR CANCER WITH EXON 14 SKIPPING MUTATION(S) OR EXON 14 SKIPPING PHENOTYPE
    Publication number: 20210283249
    Abstract: The present invention provides preparation of medicaments for use in treating and methods of treating cancer with tumors with MET exon 14 skipping mutation(s) or MET exon 14 skipping phenotype with emibetuzumab, in combination, as described herein, with merestinib.
    Type: Application
    Filed: November 10, 2017
    Publication date: September 16, 2021
    Inventor: Sau-Chi Betty YAN
  • TREATMENT OF CANCER WITH EXON 14 SKIPPING MUTATION(S) OR EXON 14 SKIPPING PHENOTYPE
    Publication number: 20210145811
    Abstract: The present invention provides a method of treating cancer with tumors bearing MET exon 14 skipping or MET exon 14 skipping phenotype comprising administering to a patient in need of such treatment an effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof:
    Type: Application
    Filed: January 29, 2021
    Publication date: May 20, 2021
    Inventor: Sau-Chi Betty YAN
  • TREATMENT OF CANCER WITH EXON 14 SKIPPING MUTATION(S) OR EXON 14 SKIPPING PHENOTYPE
    Publication number: 20200054616
    Abstract: The present invention provides a method of treating cancer with tumors bearing MET exon 14 skipping or MET exon 14 skipping phenotype comprising administering to a patient in need of such treatment an effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 9, 2017
    Publication date: February 20, 2020
    Inventor: Sau-Chi Betty YAN
  • COMBINATION OF RAMUCIRUMAB AND MERESTINIB FOR USE IN TREATMENT OF COLORECTAL CANCER
    Publication number: 20190336599
    Abstract: The present disclosure relates to a combination of an anti-human VEGFR2 antibody, preferably ramucirumab, and merestinib, or a pharmaceutically acceptable salt thereof, and to methods of using the combination to treat certain disorders, such as colorectal cancer, including advanced or metastatic colorectal cancer and/or local colorectal cancer.
    Type: Application
    Filed: April 7, 2017
    Publication date: November 7, 2019
    Applicant: Eli Lilly and Company
    Inventors: Sau-Chi Betty Yan, Richard Anthony Walgren
  • COMBINATION THERAPY WITH MERESTINIB AND ANTI-PD-L1 OR ANTI-PD-1 INHIBITORS FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20190269666
    Abstract: The present invention relates to a combination therapy with N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (merestinib, LY2801653), or a pharmaceutically acceptable salt thereof, and antibodies that bind human co-inhibitory immune checkpoints such as Programmed Death 1 Ligand 1 (PD-L1) or Programmed Death 1 (PD-1) for the treatment of various cancers.
    Type: Application
    Filed: July 21, 2017
    Publication date: September 5, 2019
    Inventors: David Arlen SCHAER, Richard A. WALGREN, Sau-Chi Betty YAN
  • COMBINATION THERAPY FOR CANCER
    Publication number: 20180207268
    Abstract: The present invention relates to a combination of an anti-human VEGFR2 antibody, preferably ramucirumab, and N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2- dihydropyridine-3-carboxamide, and to methods of using the combination to treat certain disorders, such as gastric cancer.
    Type: Application
    Filed: August 10, 2016
    Publication date: July 26, 2018
    Applicant: ImClone LLC
    Inventors: Sudhakar R. CHINTHARLAPALLI, Anthony S. FISCHL, Victoria Lynn PEEK, Richard A. WALGREN, Sau Chi Betty YAN
  • ANTI-MET IN COMBINATION WITH ANTI-VEGFR2 ANTIBODIES THERAPY FOR CANCER
    Publication number: 20160369004
    Abstract: The present invention provides preparation of medicaments for use in treating and methods of treating cancer selected from the group consisting of gastric cancer, HCC, and RCC comprising a C8-H241 Ab, preferably, C8-H241-IgG4, more preferably, emibetuzumab, in combination, as described herein, with an anti-VEGFR2 Ab, preferably, ramucirumab.
    Type: Application
    Filed: February 25, 2015
    Publication date: December 22, 2016
    Applicant: Eli Lilly and Company
    Inventors: Bronislaw Pytowski, Jonathan David Schwartz, Volker Wacheck, Sau-Chi Betty Yan
  • Formulations and methods for treating hypercoagulable states
    Patent number: 7087578
    Abstract: A method of treating a human patient with a hypercoagulable state or protein C deficiency, which comprises administering activated Protein C and protein C Zymogen.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: August 8, 2006
    Assignee: Eli Lilly and Company
    Inventors: Charles Jack Fisher, Brian Paul Barrett, Sau-Chi Betty Yan
  • Method of treating viral hemorrhagic fever
    Patent number: 6767539
    Abstract: The present invention provides a method of treatment of viral hemorrhagic fever with protein C. The claimed invention provides a needed therapy for a serious and debilitating disorder while avoiding complications such as bleeding tendency, toxicity and general side effects of currently available anti-coagulant agents.
    Type: Grant
    Filed: April 25, 2001
    Date of Patent: July 27, 2004
    Assignee: Eli Lilly and Company
    Inventors: Charles Jack Fisher, Sau-Chi Betty Yan
  • Method of treating heparin-induced thrombocytopenia
    Patent number: 6743426
    Abstract: The present invention provides a method of treatment of heparin-induced thrombocytopenia (HIT) with protein C. The claimed invention provides a needed therapy for a potentially serious and debilitating disorder while avoiding complications such as bleeding tendency, toxicity and general side effects of currently available anti-coagulant agents.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: June 1, 2004
    Assignee: Eli Lilly and Company
    Inventors: Charles Jack Fisher, Sau-Chi Betty Yan
  • Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
    Publication number: 20040087643
    Abstract: The present invention provides a method of treatment of thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) with protein C. The claimed invention provides a needed therapy for a potentially serious and debilitating disorder while avoiding complications such as bleeding tendency, toxicity and general side effects of plasma exchange or currently available anti-coagulant agents.
    Type: Application
    Filed: June 24, 2003
    Publication date: May 6, 2004
    Inventors: Charles Jack Fisher, Sau-Chi Betty Yan
  • Formulations and methods for treating hypercoagulable states
    Publication number: 20030211969
    Abstract: A method of treating a human patient with a hypercoagulable state or protein C deficiency, which comprises administering activated Protein C and protein C Zymogen.
    Type: Application
    Filed: November 19, 2002
    Publication date: November 13, 2003
    Inventors: Charles Jack Fisher, Brian Paul Barrett, Sau-Chi Betty Yan
  • Method of reducing mortality in severe sepsis
    Patent number: 6489296
    Abstract: A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surgery, severe trauma, or ARDS, which comprises administering activated protein C providing a highly selective therapeutic agent with a low potential for causing bleeding complications.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: December 3, 2002
    Assignee: Eli Lilly and Company
    Inventors: Brian William Grinnell, Daniel Lawrence Hartman, Sau-Chi Betty Yan
  • Methods for treating sepsis
    Publication number: 20020044929
    Abstract: The present invention provides a method of treatment for patients with sepsis. The claimed treatment is a combination therapy with protein C and BPI protein. Combining protein C, with its anti-coagulant/anti-inflammatory properties, and BPI, with its bactericidal and endotoxin neutralizing activities, provides an effective, synergistic therapy for sepsis that will reduce or ameliorate the adverse events and improve the clinical outcome of septic patients.
    Type: Application
    Filed: November 2, 2001
    Publication date: April 18, 2002
    Inventors: Charles Jack Fisher, Sau-Chi Betty Yan
  • Method of treating sickle cell disease or thalassemia
    Patent number: 6372213
    Abstract: The present invention provides a method of treatment of sickle cell disease (SCD) or thalassemia with protein C. The claimed invention provides a needed therapy for potentially serious and debilitating disorders while avoiding complications such as bleeding tendency, toxicity and general side effects of currently available anti-coagulant agents.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: April 16, 2002
    Assignee: Eli Lilly and Company
    Inventors: Suzane Lee Um, Barbara Gail Utterback, Sau-Chi Betty Yan
  • Methods for treating sepsis
    Patent number: 6344197
    Abstract: The present invention provides a method of treatment for patients with sepsis. The claimed treatment is a combination therapy with protein C and BPI protein. Combining protein C, with its anti-coagulant/anti-inflammatory properties, and BPI, with its bactericidal and endotoxin neutralizing activities, provides an effective, synergistic therapy for sepsis that will reduce or ameliorate the adverse events and improve the clinical outcome of septic patients.
    Type: Grant
    Filed: October 22, 1999
    Date of Patent: February 5, 2002
    Assignee: Eli Lilly and Company
    Inventors: Charles Jack Fisher, Sau-Chi Betty Yan
  • METHOD OF TREATING SICKLE CELL DISEASE OR THALASSEMIA
    Publication number: 20020012662
    Abstract: The present invention provides a method of treatment of sickle cell disease (SCD) or thalassemia with protein C. The claimed invention provides a needed therapy for potentially serious and debilitating disorders while avoiding complications such as bleeding tendency, toxicity and general side effects of currently available anticoagulant agents.
    Type: Application
    Filed: November 22, 1999
    Publication date: January 31, 2002
    Inventors: SUZANE LEE UM, BARBARA GAIL UTTERBACK, SAU-CHI BETTY YAN
  • Method of treating viral hemorrhagic fever
    Publication number: 20010028880
    Abstract: The present invention provides a method of treatment of viral hemorrhagic fever with protein C. The claimed invention provides a needed therapy for a serious and debilitating disorder while avoiding complications such as bleeding tendency, toxicity and general side effects of currently available anti-coagulant agents.
    Type: Application
    Filed: April 25, 2001
    Publication date: October 11, 2001
    Inventors: Charles Jack Fisher, Sau-Chi Betty Yan
  • Method of treating heparin-induced thrombocytopenia
    Publication number: 20010018050
    Abstract: The present invention provides a method of treatment of heparin-induced thrombocytopenia (HIT) with protein C. The claimed invention provides a needed therapy for a potentially serious and debilitating disorder while avoiding complications such as bleeding tendency, toxicity and general side effects of currently available anticoagulant agents.
    Type: Application
    Filed: May 11, 2001
    Publication date: August 30, 2001
    Inventors: Charles Jack Fisher, Sau-Chi Betty Yan
  • Method of treating viral hemorrhagic fever with activated protein C
    Patent number: 6270764
    Abstract: The present invention provides a method of treatment of viral hemorrhagic fever with activated protein C. The claimed invention provides a needed therapy for a serious and debilitating disorder while avoiding complications such as bleeding tendency, toxicity and general side effects of currently available anti-coagulant agents.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: August 7, 2001
    Assignee: Eli Lilly and Company
    Inventors: Charles Jack Fisher, Sau-Chi Betty Yan